CD44 and breast carcinoma: Grimshaw et al. [22] demonstrated that the mammosphere assay is a highly appropriate model for isolating and enriching tumorigenic stem-like cells from breast cancer patient samples and that the ability of cells to form mammospheres was not correlated with the CD44+/CD24low/− phenotype.